Antabio to develop treatment for Pseudomonas infections in cystic fibrosis patients

French biopharmaceutical company Antabio has secured a non-dilutive funding to accelerate the development of a new small molecule drug to treat chronic Pseudomonas infections in cystic fibrosis patients.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news